Arrowhead Pharmaceuticals’ (ARWR) Outperform Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their outperform rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research note issued to investors on Friday morning,Benzinga reports. Royal Bank Of Canada currently has a $100.00 target price on the biotechnology company’s stock.

Several other analysts have also commented on the stock. UBS Group initiated coverage on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 15th. They issued a “buy” rating and a $109.00 price objective for the company. Piper Sandler reiterated an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Chardan Capital reissued a “buy” rating and issued a $115.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 15th. Stifel Nicolaus lowered their target price on Arrowhead Pharmaceuticals from $104.00 to $96.00 and set a “buy” rating for the company in a research note on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $98.93.

Arrowhead Pharmaceuticals Trading Up 1.3%

Shares of ARWR opened at $47.78 on Friday. The firm’s 50-day moving average price is $63.32 and its 200-day moving average price is $71.00. The firm has a market capitalization of $6.73 billion, a price-to-earnings ratio of -9.35 and a beta of 1.34. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals has a 1-year low of $37.06 and a 1-year high of $95.49.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Adeoye Olukotun sold 2,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the transaction, the director directly owned 31,600 shares in the company, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently made changes to their positions in ARWR. Versant Capital Management Inc boosted its position in shares of Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC grew its stake in shares of Arrowhead Pharmaceuticals by 80.6% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after buying an additional 154 shares during the last quarter. Optiver Holding B.V. increased its position in Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 186 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $39,000. Finally, Allied Private Wealth LLC purchased a new position in Arrowhead Pharmaceuticals during the second quarter valued at $43,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Latest Arrowhead Pharmaceuticals News

Investors following ARWR have been watching these news items:

• Neutral Sentiment: Stifel Nicolaus kept its “buy” rating but lowered its price target to $96 from $104, reflecting a more cautious valuation while retaining a bullish view. Stifel Nicolaus rating
• Negative Sentiment: For the quarter, Arrowhead reported a $3.00-per-share loss, worse than analysts’ expected $1.52 loss. Revenue of $37.79 million also fell short of the $61.18 million consensus and declined 45.6% year over year, weighing on sentiment around the company’s results. Quarterly earnings report
• Negative Sentiment: Arrowhead reported a full-year fiscal 2026 loss of $5.11 per share. An earnings analysis also highlights the challenge of making costly R&D pay off as market sentiment toward RNA interference (RNAi) turns more skeptical. Full-year earnings results Earnings analysis

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.